FeedbackWHO_CDS_TB_2020_71_19
In MDR/RR-TB patients on longer regimens, a treatment duration of 15–17 months after culture
conversion is suggested for most patients; the duration may be modified according to the patient’s
response to therapy.
WHO_CDS_TB_2020_71_18
In MDR/RR-TB patients on longer regimens, a total treatment duration of 18–20 months is
suggested for most patients; the duration may be modified according to the patient’s response
to therapy.
WHO_CDS_TB_2020_71_17
Clavulanic acid should not be included in the treatment of MDR/RR-TB patients on longer
regimens.
WHO_CDS_TB_2020_71_16
P-aminosalicylic acid may be included in the treatment of MDR/RR-TB patients on longer
regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used or if better options
to compose a regimen are not possible.
WHO_CDS_TB_2020_71_15
Ethionamide or prothionamide may be included in the treatment of MDR/RR-TB patients on
longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used or if better
options to compose a regimen are not possible.
WHO_CDS_TB_2020_71_13
Imipenem–cilastatin or meropenem may be included in the treatment of MDR/RR-TB patients
on longer regimens.
WHO_CDS_TB_2020_71_12
Pyrazinamide may be included in the treatment of MDR/RR-TB patients on longer regimens.
WHO_CDS_TB_2020_71_11
Delamanid may be included in the treatment of MDR/RR-TB patients aged 3 years or more on
longer regimens.
WHO_CDS_TB_2020_71_10
Ethambutol may be included in the treatment of MDR/RR-TB patients on longer regimens.
WHO_CDS_TB_2020_71_1
In patients with confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis, treatment with rifampicin, ethambutol, pyrazinamide and levofloxacin is recommended for a duration of 6 months.